Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | DAO | P14920 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL365155 | 0.81 | DAO (0.42) | GSK3BDAOKDM4EMEN1ALDH1A1 | |
| SCHEMBL27390129 | 0.81 | SMN1; SMN2 (0.40) | GSK3BDAOKDM4EMEN1ALDH1A1 | |
| SCHEMBL19494595 | 0.79 | DGAT1 (0.37) | GSK3BDAOKDM4EMEN1ALDH1A1 | |
| SCHEMBL11845297 | 0.78 | ALDH1A1 (0.41) | GSK3BDAOKDM4EMEN1ALDH1A1 | |
| SCHEMBL28713332 | 0.78 | GSK3B (0.35) | GSK3BDAOALDH1A1CES2CES1 | |
| SCHEMBL456375 | 0.77 | DAO (0.42) | GSK3BDAOKDM4EALDH1A1MAPT | |
| SCHEMBL8182690 | 0.76 | GSK3B (0.52) | GSK3BMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL168008 | 0.76 | MAPT (0.40) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL20269597 | 0.73 | GAA (0.49) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL31073370 | 0.72 | GRM6 (0.35) | GSK3BMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024173646-A1 | CYCLIN-DEPENDENT KINASE DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| US-9006187-B2 | Thiophene derivative as SGLT2 inhibitor and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2015-04-14 | — | — | US | disclosed |
| US-20130172278-A1 | NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2013-07-04 | — | — | US | disclosed |
| WO-2012033390-A2 | NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172278-A1 | NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SLC5A2, SLC5A1, SLC2A2 | GSK3B 1701/4885DAO 2523/4885KDM4E 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.